Journal:

Article Title: Long Term Synaptic Depression That Is Associated with GluR1 Dephosphorylation but Not ?-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Internalization *

doi: 10.1074/jbc.M803431200

Figure Lengend Snippet: Neither GluR1 nor GluR2/3 total surface expression is changed 45 min following cLTD treatment, as determined by cross-linking assay. A, representative blots of X-linked (25.0 μg of total protein loaded) and un-X-linked (5.0 μg of total protein loaded) samples for control and cLTD conditions probed with antibodies specific for GluR1 (left group) and GluR2/3 (right group). B, representative blots of un-X-linked and X-linked (5.0μg of total protein loaded for both) samples probed with antibodies specific for PP2Aα (top bands) and synapsin (bottom bands). C and D, graphs of cumulative data comparing X-linked control and X-linked cLTD samples probed with antibodies specific for GluR1 (C) and GluR2/3 (D)(n = 8). E and F, data from C and D normalized to the transferrin receptor. G and H, graphs of cumulative data comparing the percent surface expression (see “Experimental Procedures” for explanation of calculation) between control and cLTD conditions for GluR1 (G) and GluR2/3 (H)(n = 8). I and J, graphs of cumulative data comparing un-X-linked and X-linked samples probed with antibodies specific for PP2Aα (I) and synapsin (J)(n = 8). No significant differences were observed for any of the comparisons as determined by Student's paired t test. Values represent the mean ± S.E.

Article Snippet: Primary antibodies were as follows: GluR1 and GluR2/3 (Chemicon) used at 1:3000 in BSA, phospho-Ser-845 and phospho-Ser-831 (PhosphoSolutions) used at 1:1000 in BSA, PP2Aα (BD Pharmingen) used at 1:5000 in milk, synapsin, NR2B, and NR1 (PhosphoSolutions) used at 1:2000 in BSA, the α subunit of calcium/calmodulin-dependent protein kinase II (αCaMKII) (BD Pharmingen) used at 1:3000 in BSA, phospho-Thr-286 (PhosphoSolutions) used at 1:3000 in milk, PSD-95 (Affinity Bioreagents) used at 1:5000 in BSA, and transferrin receptor (Zymed Laboratories Inc.) used at 1:1000 in milk.

Techniques: Expressing, Control

Journal: Scientific Reports

Article Title: Encapsulation of human limbus-derived stromal/mesenchymal stem cells for biological preservation and transportation in extreme Indian conditions for clinical use

doi: 10.1038/s41598-019-53315-x

Figure Lengend Snippet: Phenotypic expression of the biomarkers. Immunostaining of the encapsulated hLSMCs under transit for 3 days: Alginate encapsulated hLSMCs of both groups, stored/under transit for 3 days have shown the expression of Pax6 + , stem-cell biomarkers (ABCG2 + , p63-α + ) and the mesenchymal biomarkers (VIM + , CD90 + , CD105 + and CD45 − ) with respect to the control cells. Blue: DAPI, nuclear stain. Scale: 100 µM.

Article Snippet: The antibody panel was composed of (a) ABCG2 (1:100, 18841, Santa Cruz Biotechnology, USA), Pax6 (1:300, 901301, BioLegend, USA), p63-α (1:100, 4892S, Cell Signalling technology, USA) and Col-III (1:100, ab7778, Abcam, UK), as positive markers of the human limbal stem cell phenotype; HLA-DR (1:100, ab55152, Abcam, UK), and CD45 (1:100, 13197, Cell Signalling Technology, USA) as negative marker for mesenchymal origin, (b) CD73 (1:100, 13160, Cell Signalling Technology, USA), CD105 (1:100, 376381, Santa Cruz Biotechnology, USA), and VIM (1:100, 6260, Santa Cruz Biotechnology, USA) as positive markers of the mesenchymal phenotype.

Techniques: Expressing, Immunostaining, Control, Staining

Journal: Scientific Reports

Article Title: Encapsulation of human limbus-derived stromal/mesenchymal stem cells for biological preservation and transportation in extreme Indian conditions for clinical use

doi: 10.1038/s41598-019-53315-x

Figure Lengend Snippet: Quantification of the gene expression using real-time PCR. Immunostaining of the encapsulated hLSMCs under transit for 5 days: Alginate encapsulated hLSMCs stored at 4 °C did not show expression of the stem-cell (ABCG2 − ). The RT group cells have showed similar phenotype as the control group (ABCG2 + , Pax6 + p63-α + , VIM + , CD90 + , CD105 + , CD45 − , HLADR + , Col-III + , and CD73 + ). Blue: DAPI, nuclear stain. Scale : 100 µM.

Article Snippet: The antibody panel was composed of (a) ABCG2 (1:100, 18841, Santa Cruz Biotechnology, USA), Pax6 (1:300, 901301, BioLegend, USA), p63-α (1:100, 4892S, Cell Signalling technology, USA) and Col-III (1:100, ab7778, Abcam, UK), as positive markers of the human limbal stem cell phenotype; HLA-DR (1:100, ab55152, Abcam, UK), and CD45 (1:100, 13197, Cell Signalling Technology, USA) as negative marker for mesenchymal origin, (b) CD73 (1:100, 13160, Cell Signalling Technology, USA), CD105 (1:100, 376381, Santa Cruz Biotechnology, USA), and VIM (1:100, 6260, Santa Cruz Biotechnology, USA) as positive markers of the mesenchymal phenotype.

Techniques: Gene Expression, Real-time Polymerase Chain Reaction, Immunostaining, Expressing, Control, Staining

Journal: Scientific Reports

Article Title: Encapsulation of human limbus-derived stromal/mesenchymal stem cells for biological preservation and transportation in extreme Indian conditions for clinical use

doi: 10.1038/s41598-019-53315-x

Figure Lengend Snippet: Tabular format denoting the number of cells showing positive expression of the phenotypic biomarkers.

Article Snippet: The antibody panel was composed of (a) ABCG2 (1:100, 18841, Santa Cruz Biotechnology, USA), Pax6 (1:300, 901301, BioLegend, USA), p63-α (1:100, 4892S, Cell Signalling technology, USA) and Col-III (1:100, ab7778, Abcam, UK), as positive markers of the human limbal stem cell phenotype; HLA-DR (1:100, ab55152, Abcam, UK), and CD45 (1:100, 13197, Cell Signalling Technology, USA) as negative marker for mesenchymal origin, (b) CD73 (1:100, 13160, Cell Signalling Technology, USA), CD105 (1:100, 376381, Santa Cruz Biotechnology, USA), and VIM (1:100, 6260, Santa Cruz Biotechnology, USA) as positive markers of the mesenchymal phenotype.

Techniques: Expressing, Control, Biomarker Discovery